Advancements in the Management of Gynecological Cancers: ESMO 2024 - Episode 1

Approaching Biomarker Testing and Frontline Maintenance Therapy for Advanced Ovarian Cancer

September 30, 2024

Angeles Alvarez Secord, MD, MHSc , Dana M. Chase, MD, FACOG, Bhavana Pothuri, MD, Premal H. Thaker, MD, MS, Thomas C. Krivak, MD

Panelists discuss frontline maintenance therapies for advanced ovarian cancer, focusing on the impact of BRCA and HRD statuses on treatment selection and the choice between combination therapy (PARPi + bev) and monotherapy.

Now Viewing

EP. 1: Approaching Biomarker Testing and Frontline Maintenance Therapy for Advanced Ovarian Cancer

EP. 2: Key Findings from the PRIMA Trial: Niraparib in 1L Maintenance for Advanced Ovarian Cancer

EP. 3: Duration of PARP Inhibitor Maintenance Therapy for Ovarian Cancer

EP. 4: Emerging Combinations in Maintenance Therapy for Ovarian Cancer

EP. 5: Optimizing Ovarian Cancer Care: PARP Resistance, Management of Oligoprogression, and Adverse Event Mitigation

EP. 6: Use of Trastuzumab Deruxtecan in Ovarian Cancer

EP. 7: Antibody-Drug Conjugates in Ovarian Cancer: Emerging Data and Treatment Integration

EP. 8: Navigating Treatment Strategies for Advanced Cervical Cancer: Localized Therapy, KEYNOTE-A18 Trial Data, and Frontline Approaches

EP. 9: Integrating Tisotumab Vedotin into Ovarian Cancer Therapy

EP. 10: Biomarker Testing in Advanced Endometrial Cancer: Approach, Key Markers, and Impact on Treatment Decisions

EP. 11: Managing Recurrent Endometrial Cancer: Treatment Strategies and RUBY Trial Insights

EP. 12: Durvalumab in Endometrial Cancer: DUO-E Trial Updates

EP. 13: Innovative Combination Strategies for Endometrial Cancer: Updates from LEAP and KEYNOTE-B21 Trials

EP. 14: T-DXd in Advanced Endometrial Cancer

EP. 15: Emerging ADCs in Advanced Endometrial Cancer: Anti-TROP2 and Anti-FR Agents

Video content above is prompted by the following:

How do you typically approach biomarker testing for advanced ovarian cancer?
When do you test and what type of testing do you perform?
Which biomarkers do you generally access (e.g., BRCA1/2, HRD, etc) and how do results help guide your treatment approach?
Briefly review frontline maintenance therapy options for advanced ovarian cancer and discuss key factors that drive your selection among available therapies.
How do BRCA and HRD statuses influence your choice of maintenance therapy?
When may you opt for a combination (PARPi + bev) vs monotherapy approach?